MedTrace Logo

Pembrolizumab Plus Olaparib in Patients With Recurrent Cervical Cancer

NCT04641728 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2022-08-09

No results posted yet for this study

Summary

This trial is a multicenter, single-arm, phase 2 study of pembrolizumab in combination with olaparib in recurrent or metastatic cervical cancer patients who had disease progression during or after platinum-based chemotherapy.

Conditions

Interventions

DRUG

Pembrolizumab

pembrolizumab 200 mg every three weeks (Q3W)

DRUG

Olaparib

olaparib 300 mg twice daily (BID)

Sponsors & Collaborators

  • Tokyo University

    collaborator OTHER

  • National Cancer Center, Japan

    collaborator OTHER_GOV

  • Cancer Institute Hospital, Japan

    collaborator OTHER

  • Aichi Cancer Center

    collaborator OTHER

  • Saitama Medical University International Medical Center

    lead OTHER

Principal Investigators

  • Kosei Hasegawa, MD, PhD · Saitama Medical University International Medical Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-01
Primary Completion
2022-12-31
Completion
2023-12-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04641728 on ClinicalTrials.gov